Partnering and Out-licensing

As a small company, Ultupharma’s business model is to patent new inventions and to out-license, or enter into collaborations at an early stage. The ULT1, ULT2 and ULT3 patents are open for out-licensing/collaboration to one or more partners.

A presentation of patented new antibiotics is available on request. This gives details about MIC values, FoR, mechanisms of action, animal studies and clinical possibilities.




Hemsida Uppsala